| 1 | Gestational age at birth (child effect) | GCST90268421 | 78.50 |
| 2 | Osteoporosis NOS (PheCode 743.11) | GCST90476260 | 76.50 |
| 3 | Osteoporosis (PheCode 743.1) | GCST90476259 | 69.98 |
| 4 | Sleep apnea (MTAG) (adjusted for BMI) | GCST90267364 | 54.67 |
| 5 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 77) | GCST90320896 | 51.04 |
| 6 | IDP T1 FIRST left putamen volume | GCST90002440 | 50.70 |
| 7 | Other specified and unspecified disorders of lens | FING00001101 | 47.07 |
| 8 | DTI autoptx FA str r tract | GCST90385136 | 43.26 |
| 9 | DTI autoptx L2 str r tract | GCST90385190 | 42.75 |
| 10 | aparc-DKTatlas rh volume parahippocampal | GCST90002907 | 40.60 |
| 11 | BA-exvivo lh volume BA3a | GCST90002837 | 38.41 |
| 12 | height (minimum, inv-normal transformed) | GCST90475365 | 38.39 |
| 13 | Hereditary corneal dystrophies | FING00000611 | 38.39 |
| 14 | DTI autoptx FA slf l tract | GCST90385133 | 38.33 |
| 15 | What is your height? (cm, inv-normal transformed) | GCST90475368 | 37.47 |
| 16 | height (mean, inv-normal transformed) | GCST90475362 | 37.23 |
| 17 | Height (maximum, inv-normal transformed) | GCST90475359 | 36.43 |
| 18 | DTI autoptx MD cgc r tract | GCST90385225 | 36.27 |
| 19 | Phosphatidylcholine (14:0_22:6) levels | GCST90024234 | 35.81 |
| 20 | BCAN/NPTXR ratio | GCST90313482 | 35.59 |
| 21 | EGFR/FAP ratio | GCST90314613 | 35.42 |
| 22 | Osteoporosis, osteopenia and pathological fracture (PheCode 743) | GCST90476258 | 35.00 |
| 23 | Scoliosis | FING00001281 | 34.82 |
| 24 | DTI autoptx L3 str r tract | GCST90385217 | 34.70 |
| 25 | Forced vital capacity (FVC) | Spirometry | UKBB00000254 | 34.68 |
| 26 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502411 | 34.35 |
| 27 | DTI TBSS FA Superior longitudinal fasciculus L | GCST90384421 | 33.37 |
| 28 | Volume of left paralaminar nucleus | GCST90474985 | 32.92 |
| 29 | ALB levels | GCST90475106 | 31.32 |
| 30 | ADAMTSL2 levels | GCST90468228 | 30.66 |
| 31 | aparc-DKTatlas rh area lateraloccipital | GCST90003274 | 30.65 |
| 32 | Spinal stenosis | musculoskeletal | UKBB00000792 | 30.59 |
| 33 | Operation code - spine or back surgery | Operations | UKBB00000565 | 30.16 |
| 34 | DTI autoptx L3 str l tract | GCST90385216 | 29.95 |
| 35 | Left-hemisphere limbic network to right-hemisphere limbic network white-matter structural connectivity | GCST90302733 | 29.55 |
| 36 | aparc-Desikan rh volume parahippocampal | GCST90002816 | 29.51 |
| 37 | Alpha angle | GCST90129635 | 29.46 |
| 38 | aparc-Desikan lh thickness GlobalMeanThickness | GCST90003445 | 29.14 |
| 39 | SIL1 levels | GCST90470638 | 29.13 |
| 40 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 80) | GCST90320643 | 28.99 |
| 41 | Standing height (UKB data field 50) | GCST90468178 | 28.80 |
| 42 | aparc-a2009s rh area Pole-occipital | GCST90003412 | 28.32 |
| 43 | ALB levels | GCST90475103 | 28.09 |
| 44 | PDCD6 levels | GCST90470183 | 27.72 |
| 45 | Operative procedures - Primary repair of inguinal hernia using insert of prosthetic material | Summary Operations | UKBB00000587 | 27.67 |
| 46 | ASPN levels | GCST90468377 | 27.58 |
| 47 | Autorefraction - 3mm strong meridian angle (left) | Eyesight | UKBB00000067 | 27.47 |
| 48 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 103) | GCST90320922 | 27.30 |
| 49 | IDP T1 FAST ROIs R occ pole | GCST90002546 | 27.24 |
| 50 | ITGA2 levels | GCST90469634 | 27.10 |
| 51 | T1 FreeSurfer a2009s lh G cuneus area | GCST90384678 | 27.08 |
| 52 | Intraocular pressure (confirmatory factor analysis Factor 26) | GCST90309360 | 27.03 |
| 53 | Left-hemisphere control network to putamen white-matter structural connectivity | GCST90302754 | 26.79 |
| 54 | Intra-ocular pressure, Goldmann-correlated (right) | Intraocular pressure | UKBB00000377 | 26.70 |
| 55 | aparc-DKTatlas lh area pericalcarine | GCST90003253 | 26.60 |
| 56 | Sitting height | Body size measures | UKBB00000771 | 26.60 |
| 57 | Height (baseline) | GCST90565843 | 26.41 |
| 58 | aparc-Desikan rh area lateraloccipital | GCST90003117 | 26.29 |
| 59 | Forced expiratory volume in 1-second (FEV1), predicted | Spirometry | UKBB00000252 | 26.28 |
| 60 | Height | GCST90302890 | 26.22 |
| 61 | Ribothymidine levels in chronic kidney disease | GCST90257554 | 26.14 |
| 62 | Pulse pressure | GCST90472785 | 25.95 |
| 63 | RFC4 levels | GCST90470460 | 25.87 |
| 64 | Carpal tunnel syndrome | FING00000257 | 25.58 |
| 65 | IGFBP3 levels | GCST90469529 | 25.54 |
| 66 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 102) | GCST90320921 | 25.47 |
| 67 | Seated height | Body size measures | UKBB00000763 | 25.15 |
| 68 | Sulcal opening distance of the right calloso-marginal posterior fissure | GCST90104946 | 24.95 |
| 69 | ANGPTL2 levels | GCST90468303 | 24.92 |
| 70 | BA-exvivo lh area V1 | GCST90003216 | 24.51 |
| 71 | Height | GCST90278637 | 24.50 |
| 72 | PADI2 levels | GCST90470142 | 24.44 |
| 73 | MTHFSD levels | GCST90469956 | 24.33 |
| 74 | FAP levels | GCST90469189 | 24.09 |
| 75 | Fracture of forearm | GCST90281273 | 23.94 |
| 76 | Pulse pressure | GCST90301703 | 23.91 |
| 77 | Intra-ocular pressure, Goldmann-correlated (left) | Intraocular pressure | UKBB00000376 | 23.83 |
| 78 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 46) | GCST90320609 | 23.56 |
| 79 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502075 | 23.42 |
| 80 | Coronary atherosclerosis | FING00000359 | 23.38 |
| 81 | RAD23B levels | GCST90470418 | 23.17 |
| 82 | Bioavailable testosterone levels | GCST90012104 | 23.12 |
| 83 | HEXIM1/IKBKG ratio | GCST90315045 | 23.00 |
| 84 | Central corneal thickness | GCST006366 | 22.99 |
| 85 | Appendicular lean mass | GCST90000026 | 22.97 |
| 86 | Hallux valgus (Bunion) (PheCode 735.3) | GCST90476251 | 22.89 |
| 87 | Perforation of tympanic membrane | FING00001155 | 22.70 |
| 88 | Pulse pressure | GCST90301701 | 22.63 |
| 89 | Calcific aortic valvular stenosis, operated | FING00000234 | 22.48 |
| 90 | Atherosclerosis of native arteries of the extremities with intermittent claudication (PheCode 440.22) | GCST90475991 | 22.32 |
| 91 | Hernia | FING00000616 | 22.23 |
| 92 | Autorefraction - 6mm asymmetry index (right) | Eyesight | UKBB00000074 | 22.21 |
| 93 | Deep bite | FING00000380 | 22.15 |
| 94 | REST UKBBICA NET100 1287 | GCST90387141 | 22.11 |
| 95 | Occlusion and stenosis of precerebral arteries (PheCode 433.1) | GCST90475986 | 22.08 |
| 96 | Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels | GCST90200098 | 22.01 |
| 97 | aparc-Desikan lh area pericalcarine | GCST90003093 | 21.87 |
| 98 | Height | GCST90025949 | 21.81 |
| 99 | Height (standard GWA) | GCST90267284 | 21.59 |
| 100 | Appendicular lean mass | GCST90000025 | 21.42 |
| 101 | Lung function (FVC) | GCST007429 | 21.27 |
| 102 | Abdominal aortic aneurysm (PheCode 442.11) | GCST90475994 | 21.16 |
| 103 | PALM2 levels | GCST90470152 | 21.07 |
| 104 | Waist-to-Hip ratio | Body measurement | UKBB00000905 | 21.03 |
| 105 | PTGES2 levels | GCST90470369 | 21.02 |
| 106 | Ventral hernia (PheCode 550.5) | GCST90476063 | 20.88 |
| 107 | Hallux valgus (acquired) | FING00000601 | 20.76 |
| 108 | UBE2L6 levels | GCST90471001 | 20.75 |
| 109 | Ischaemic heart disease, wide definition | FING00000703 | 20.66 |
| 110 | Succinylcarnitine levels | GCST90243874 | 20.65 |
| 111 | Anterior thigh muscle volume | GCST90267349 | 20.62 |
| 112 | Left-hemisphere visual network to thalamus white-matter structural connectivity | GCST90302662 | 20.59 |
| 113 | Hard cardiovascular diseases | FING00000602 | 20.59 |
| 114 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502580 | 20.57 |
| 115 | Inguinal hernia | digestive | UKBB00000362 | 20.45 |
| 116 | Aortic aneurysm (PheCode 442.1) | GCST90475993 | 20.36 |
| 117 | Takes medication for acid reflux/GERD? | GCST90475321 | 20.32 |
| 118 | ANGPTL3/TFPI ratio | GCST90313270 | 20.27 |
| 119 | aseg global volume CC-Posterior | GCST90002607 | 20.22 |
| 120 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 121) | GCST90320940 | 20.17 |
| 121 | Plasma N-acetylhistidine levels in chronic kidney disease | GCST90265576 | 20.14 |
| 122 | Hereditary ataxia | FING00000610 | 20.11 |
| 123 | Waist-to-hip ratio adjusted for BMI | GCST90025996 | 20.09 |
| 124 | DTI autoptx L2 slf l tract | GCST90385187 | 19.93 |
| 125 | CTSO levels | GCST90468915 | 19.85 |
| 126 | aparc-pial rh area lateraloccipital | GCST90003184 | 19.80 |
| 127 | Physical function (baseline) | GCST90565837 | 19.68 |
| 128 | C-reactive protein levels (CRP.4337.49.2) | GCST90240503 | 19.64 |
| 129 | CDKN1A/FXN ratio | GCST90313971 | 19.61 |
| 130 | IL1RL1 levels | GCST90241581 | 19.57 |
| 131 | BST2 levels | GCST90468475 | 19.57 |
| 132 | Other cancer | GCST90475181 | 19.51 |
| 133 | Autorefraction - 3mm cylindrical power (left) | Eyesight | UKBB00000062 | 19.49 |
| 134 | Forced vital capacity FVC Z score (UKB data field 20257) | GCST90468167 | 19.43 |
| 135 | Other aneurysm (PheCode 442) | GCST90475992 | 19.40 |
| 136 | Pulse pressure | GCST90301702 | 19.39 |
| 137 | Fracture of forearm | FING00000554 | 19.29 |
| 138 | Macular puckering of retina (PheCode 362.26) | GCST90475854 | 19.24 |
| 139 | GLB1/PCSK9 ratio | GCST90314933 | 19.06 |
| 140 | Appendicular lean mass | GCST90000027 | 18.93 |
| 141 | COL24A1 levels | GCST90468814 | 18.83 |
| 142 | Diacylglycerol_36:3_[M+H-H2O]1+ levels | GCST90060189 | 18.79 |
| 143 | Coronary artery bypass grafting | FING00000358 | 18.73 |
| 144 | Abdominal hernia (PheCode 550) | GCST90476059 | 18.72 |
| 145 | rfMRI connectivity (ICA100 edge 380) | GCST90005233 | 18.71 |
| 146 | X-24947 levels | GCST90200651 | 18.57 |
| 147 | PCSK9 levels | GCST90428110 | 18.56 |
| 148 | Height | GCST90018739 | 18.56 |
| 149 | NAAA levels | GCST90469991 | 18.53 |
| 150 | Myopia (PheCode 367.1) | GCST90475880 | 18.52 |
| 151 | Height, inverse-rank normalized | FING00000607 | 18.49 |
| 152 | CTSO levels | GCST90179277 | 18.46 |
| 153 | Other disorders of cornea | FING00001022 | 18.41 |
| 154 | Phosphatidylcholine (40:8) levels | GCST90025538 | 18.38 |
| 155 | Emphysema (PheCode 496.1) | GCST90476028 | 18.37 |
| 156 | Coronary atherosclerosis (PheCode 411.4) | GCST90043957 | 18.33 |
| 157 | Standing height | Body size measures | UKBB00000796 | 18.22 |
| 158 | COL6A3/OGN ratio | GCST90314177 | 18.22 |
| 159 | aparc-a2009s lh thickness S-intrapariet+P-trans | GCST90003658 | 18.22 |
| 160 | Calcific aortic valve stenosis | GCST90310293 | 18.20 |
| 161 | DTI TBSS L3 Superior corona radiata R | GCST90384548 | 18.19 |
| 162 | IDP dMRI TBSS L1 Cingulum cingulate gyrus R | GCST90004109 | 18.16 |
| 163 | Coxarthrosis, primary | FING00000363 | 18.13 |
| 164 | aparc-a2009s lh area S-calcarine | GCST90003340 | 18.12 |
| 165 | TNN levels | GCST90470927 | 18.10 |
| 166 | Height (weighted GWA) | GCST90267285 | 17.97 |
| 167 | PLXDC2 levels | GCST90470264 | 17.95 |
| 168 | CEP112 levels | GCST90468708 | 17.83 |
| 169 | DTI TBSS L2 Superior longitudinal fasciculus L | GCST90384517 | 17.82 |
| 170 | IDP dMRI ProbtrackX MO atr r | GCST90004003 | 17.74 |
| 171 | A body shape index | GCST90020024 | 17.70 |
| 172 | Job involves shift work | Employment | UKBB00000385 | 17.70 |
| 173 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 87) | GCST90320906 | 17.61 |
| 174 | aparc-Desikan lh area lingual | GCST90003085 | 17.59 |
| 175 | FUS levels | GCST90469278 | 17.59 |
| 176 | NGRN levels | GCST90470045 | 17.57 |
| 177 | PCSK9 levels | GCST90470177 | 17.53 |
| 178 | Inguinal hernia | Hernia | UKBB00000363 | 17.52 |
| 179 | CTSD/PRCP ratio | GCST90314312 | 17.51 |
| 180 | CFB levels | GCST90240778 | 17.50 |
| 181 | HMOX2/TDRKH ratio | GCST90315067 | 17.50 |
| 182 | Spinal stenosis | FING00001322 | 17.46 |
| 183 | Corneal hysteresis (right) | Intraocular pressure | UKBB00000149 | 17.37 |
| 184 | DIABLO/PRKAR1A ratio | GCST90314469 | 17.36 |
| 185 | Spinal stenosis of lumbar region (PheCode 720.1) | GCST90476234 | 17.32 |
| 186 | Major coronary heart disease event | FING00000746 | 17.28 |
| 187 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502632 | 17.27 |
| 188 | FOXJ3 levels | GCST90469264 | 17.27 |
| 189 | ATRN levels | GCST90468400 | 17.25 |
| 190 | Volume of left basal nucleus | GCST90474877 | 17.13 |
| 191 | Corneal resistance factor | GCST90100568 | 17.10 |
| 192 | FST/FSTL3 ratio | GCST90314882 | 17.07 |
| 193 | Iliac isthmus breadth | GCST90448907 | 17.03 |
| 194 | DTI TBSS L3 Superior longitudinal fasciculus L | GCST90384565 | 17.01 |
| 195 | HippSubfield lh volume Whole-hippocampal-head | GCST90002688 | 17.01 |
| 196 | VSNL1 levels | GCST90471054 | 16.99 |
| 197 | VNN2 levels | GCST90618510 | 16.90 |
| 198 | Plasma succinylcarnitine (C4-DC) levels in chronic kidney disease | GCST90265998 | 16.85 |
| 199 | Kidney volume | GCST90016670 | 16.83 |
| 200 | Angina pectoris | GCST90018573 | 16.81 |
| 201 | PTP4A3 levels | GCST90470375 | 16.79 |
| 202 | IL1RL2 levels | GCST90469575 | 16.75 |
| 203 | Osteoporosis | musculoskeletal | UKBB00000598 | 16.68 |
| 204 | ALB levels | GCST90475100 | 16.67 |
| 205 | Polyunsaturated fatty acid levels | GCST90499271 | 16.66 |
| 206 | PDAP1 levels | GCST90470179 | 16.63 |
| 207 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 122) | GCST90320941 | 16.62 |
| 208 | IGFBP4/OGN ratio | GCST90315134 | 16.61 |
| 209 | Body size (confirmatory factor analysis Factor 21) | GCST90309355 | 16.59 |
| 210 | Hippocampal subfield left CA3 volume (body) | GCST90267940 | 16.56 |
| 211 | Volume of left whole amygdala | GCST90474898 | 16.54 |
| 212 | Osteoporosis NOS | musculoskeletal | UKBB00000599 | 16.49 |
| 213 | Fractures | GCST006980 | 16.48 |
| 214 | Lysophosphatidylcholine (22:6) [sn2] levels | GCST90024185 | 16.40 |
| 215 | Angina pectoris | FING00000086 | 16.34 |
| 216 | FUCA1 levels | GCST90469275 | 16.29 |
| 217 | aparc-DKTatlas lh area lingual | GCST90003245 | 16.27 |
| 218 | LAMB1 levels | GCST90469732 | 16.24 |
| 219 | DTI TBSS L2 Superior fronto-occipital fasciculus R | GCST90384518 | 16.24 |
| 220 | Heel quantitative ultrasound index (QUI), direct entry | Bone-densitometry of heel | UKBB00000324 | 16.15 |
| 221 | Heel bone mineral density (BMD) T-score, automated | Bone-densitometry of heel | UKBB00000318 | 16.15 |
| 222 | Coxarthrosis, primary, with hip surgery | FING00000364 | 16.11 |
| 223 | IDP T1 FAST ROIs R hippocampus | GCST90002556 | 16.11 |
| 224 | Heel bone mineral density (BMD) | Bone-densitometry of heel | UKBB00000315 | 16.08 |
| 225 | Sphingomyelin_42:2_[M+H]1+ levels | GCST90060403 | 16.07 |
| 226 | CST3/IGFBP6 ratio | GCST90314293 | 16.05 |
| 227 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502160 | 15.97 |
| 228 | CES1 levels | GCST90468718 | 15.95 |
| 229 | Hypermetropia (PheCode 367.8) | GCST90475882 | 15.90 |
| 230 | Volume of right basal nucleus | GCST90474910 | 15.87 |
| 231 | DTI autoptx MD str r tract | GCST90385244 | 15.82 |
| 232 | CC2D1A/STIP1 ratio | GCST90313665 | 15.75 |
| 233 | AOC3 levels | GCST90468322 | 15.72 |
| 234 | PON3 levels | GCST90470287 | 15.71 |
| 235 | IDP dMRI TBSS L2 Anterior corona radiata L | GCST90004146 | 15.70 |
| 236 | Plasma N-acetyltaurine levels in chronic kidney disease | GCST90265600 | 15.68 |
| 237 | Cardiomyopathy | GCST90399705 | 15.67 |
| 238 | Abdominal hernia | digestive | UKBB00000002 | 15.67 |
| 239 | GLRX5 levels | GCST90469361 | 15.66 |
| 240 | ERBB3 levels | GCST90469140 | 15.63 |
| 241 | Adenomyosis (Endometriosis of uterus) | FING00000042 | 15.61 |
| 242 | CDON levels | GCST90468687 | 15.59 |
| 243 | SCAMP3/VPS53 ratio | GCST90315807 | 15.58 |
| 244 | Iron deficiency anemia secondary to blood loss (chronic) (PheCode 280.2) | GCST90475770 | 15.56 |
| 245 | OXCT1 levels | GCST90470138 | 15.48 |
| 246 | wg lh intensity-contrast temporalpole | GCST90003824 | 15.39 |
| 247 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 42) | GCST90320605 | 15.35 |
| 248 | IDP T1 FAST ROIs L parahipp gyrus post | GCST90002519 | 15.35 |
| 249 | IL1B levels | GCST90469570 | 15.28 |
| 250 | COL9A1 levels | GCST90468822 | 15.27 |
| 251 | aparc-a2009s rh volume S-oc-middle+Lunatus | GCST90003055 | 15.23 |
| 252 | ARF6 levels | GCST90468348 | 15.18 |
| 253 | Prescriptions - latanoprost | prostaglandin analog | UKBB00000686 | 15.18 |
| 254 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 11) | GCST90320574 | 15.17 |
| 255 | Smoking dependency | FING00001315 | 15.14 |
| 256 | Wears glasses or contact lenses (UKB data field 2207) | GCST90042875 | 15.14 |
| 257 | Sleep apnea (MTAG) | GCST90267362 | 15.14 |
| 258 | PSME2/RBKS ratio | GCST90315737 | 15.11 |
| 259 | Follicular cysts of skin and subcutaneous tissue | FING00000547 | 15.09 |
| 260 | Average diameter for VLDL particles (UKB data field 23431) | GCST90269528 | 15.06 |
| 261 | Pain type(s) experienced in last month - Back pain | Pain | UKBB00000626 | 15.05 |
| 262 | LGALS8/SOD2 ratio | GCST90315320 | 15.05 |
| 263 | BTD levels | GCST90468477 | 15.03 |
| 264 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 107) | GCST90320670 | 15.02 |
| 265 | BCL2 levels | GCST90468433 | 15.02 |
| 266 | Heel Broadband ultrasound attenuation, direct entry | Bone-densitometry of heel | UKBB00000321 | 14.97 |
| 267 | Waist-hip index | GCST90020027 | 14.96 |
| 268 | CDHR2 levels | GCST90468679 | 14.96 |
| 269 | Omega-3 fatty acids to total fatty acids percentage | GCST90502463 | 14.93 |
| 270 | Chronic osteomyelitis (PheCode 710.12) | GCST90476223 | 14.93 |
| 271 | HippSubfield lh volume GC-ML-DG-body | GCST90002681 | 14.89 |
| 272 | Acute alcohol intoxication, ICD10 | FING00000015 | 14.88 |
| 273 | Waist-to-hip ratio adjusted for BMI | GCST90020025 | 14.88 |
| 274 | Age-related eyesight deterioration (confirmatory factor analysis Factor 27) | GCST90309361 | 14.84 |
| 275 | Coronary revascularization (ANGIO or CABG) | FING00000360 | 14.82 |
| 276 | Eustachian tube disorders (PheCode 381.2) | GCST90475904 | 14.80 |
| 277 | Impedance of arm left (UKB data field 23110) | GCST90468171 | 14.79 |
| 278 | Posterior thigh muscle volume | GCST90267353 | 14.78 |
| 279 | Impedance of arm (right) | Impedance measures | UKBB00000357 | 14.73 |
| 280 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24) | GCST90320587 | 14.72 |
| 281 | BCAN/MOG ratio | GCST90313480 | 14.60 |
| 282 | DTI TBSS L3 Retrolenticular part of internal capsule L | GCST90384545 | 14.60 |
| 283 | Triglycerides in very large VLDL (UKB data field 23494) | GCST90269591 | 14.55 |
| 284 | Volume of right medial nucleus | GCST90474925 | 14.53 |
| 285 | Synovitis and tenosynovitis (PheCode 727.1) | GCST90476242 | 14.53 |
| 286 | Coxarthrosis | FING00000362 | 14.51 |
| 287 | Blood cell traits latent factor 20 (red cell) | GCST90559262 | 14.48 |
| 288 | BA-exvivo lh area V2 | GCST90003217 | 14.47 |
| 289 | Sphingomyelin_42:3_[M+H]1+ levels | GCST90060399 | 14.47 |
| 290 | NCK2/PLA2G4A ratio | GCST90315524 | 14.46 |
| 291 | Hand grip strength right (UKB data field 47) | GCST90468169 | 14.44 |
| 292 | Cardiomyopathy (PheCode 425) | GCST90475949 | 14.39 |
| 293 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 40) | GCST90320859 | 14.33 |
| 294 | Enteritis due to Yersinia enterocolitica | FING00000505 | 14.26 |
| 295 | HippSubfield lh volume GC-ML-DG-head | GCST90002679 | 14.25 |
| 296 | Phenylalanine levels | GCST90243407 | 14.25 |
| 297 | Mononeuropathies of upper limb | Nerve, nerve root and plexus disorders | UKBB00000481 | 14.22 |
| 298 | HRC levels | GCST90469475 | 14.22 |
| 299 | Tetradecadienedioate (C14:2-DC) metabolite level | GCST90616275 | 14.22 |
| 300 | AmygNuclei lh volume Whole-amygdala | GCST90002657 | 14.17 |
| 301 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90132630 | 14.16 |
| 302 | Inguinal hernia | FING00000681 | 14.16 |
| 303 | Corneal resistance factor (right) | Intraocular pressure | UKBB00000151 | 14.12 |
| 304 | ACE2 levels | GCST90468197 | 14.10 |
| 305 | SCARA5/TNC ratio | GCST90315810 | 14.08 |
| 306 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 82) | GCST90320645 | 14.08 |
| 307 | Deforming dorsopathies | FING00000385 | 14.07 |
| 308 | ITGA11 levels | GCST90469633 | 14.07 |
| 309 | IDP dMRI ProbtrackX L3 unc r | GCST90004326 | 14.06 |
| 310 | Stroke, excluding SAH | FING00001337 | 14.06 |
| 311 | Autorefraction - 3mm weak meridian angle (left) | Eyesight | UKBB00000071 | 14.06 |
| 312 | FABP5 levels | GCST90469177 | 13.96 |
| 313 | ADGRD1 levels | GCST90468235 | 13.95 |
| 314 | IL22 levels | GCST90088066 | 13.91 |
| 315 | Waist circumference adjusted for body mass index | GCST90020029 | 13.89 |
| 316 | Multi-trait sex score | GCST90270118 | 13.84 |
| 317 | Octadecanedioylcarnitine (C18-DC) levels | GCST90199992 | 13.84 |
| 318 | aparc-Desikan lh thickness postcentral | GCST90003466 | 13.83 |
| 319 | Triglycerides in large VLDL (UKB data field 23501) | GCST90269598 | 13.78 |
| 320 | IGFBP6/SMOC2 ratio | GCST90315138 | 13.76 |
| 321 | Lung cancer | GCST90011812 | 13.74 |
| 322 | Hand grip strength left (UKB data field 46) | GCST90468168 | 13.71 |
| 323 | Hand grip strength (baseline) | GCST90565845 | 13.64 |
| 324 | F10 levels | GCST90469163 | 13.60 |
| 325 | Atherosclerosis of the extremities (PheCode 440.2) | GCST90475990 | 13.53 |
| 326 | Volume of left central nucleus | GCST90474883 | 13.52 |
| 327 | aparc-pial lh area pericalcarine | GCST90003161 | 13.51 |
| 328 | DLK1/FAP ratio | GCST90314491 | 13.50 |
| 329 | wg lh intensity-contrast entorhinal | GCST90003797 | 13.50 |
| 330 | aparc-DKTatlas lh thickness postcentral | GCST90003560 | 13.49 |
| 331 | TOMM20 levels | GCST90470931 | 13.45 |
| 332 | Omega-3 fatty acids to total fatty acids percentage | GCST90502088 | 13.45 |
| 333 | Subpubic angle | GCST90448908 | 13.44 |
| 334 | CLEC14A/PIK3IP1 ratio | GCST90314080 | 13.41 |
| 335 | Mean volume of bilateral amygdala | GCST90474901 | 13.40 |
| 336 | Pelvic height | GCST90448912 | 13.38 |
| 337 | Total lipids in very large VLDL (UKB data field 23489) | GCST90269586 | 13.37 |
| 338 | 4-acetamidobutanoate levels | GCST90243440 | 13.36 |
| 339 | Aortic aneurysm | FING00000102 | 13.36 |
| 340 | Left-hemisphere visual network to left-hemisphere somatomotor network white-matter structural connectivity | GCST90302649 | 13.33 |
| 341 | Diaphragmatic hernia | FING00000419 | 13.30 |
| 342 | ALB levels | GCST90092807 | 13.30 |
| 343 | aparc-DKTatlas rh area cuneus | GCST90003268 | 13.27 |
| 344 | Phospholipids in small VLDL | GCST90499881 | 13.26 |
| 345 | Impedance of arm (left) | Impedance measures | UKBB00000356 | 13.26 |
| 346 | GSTA3 levels | GCST90469412 | 13.25 |
| 347 | MAMDC2 levels | GCST90469841 | 13.21 |
| 348 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502592 | 13.18 |
| 349 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502166 | 13.16 |
| 350 | MYOC levels | GCST90422825 | 13.13 |
| 351 | Sphingomyelin_36:1_[M+H]1+ levels | GCST90060266 | 13.09 |
| 352 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 85) | GCST90320904 | 13.09 |
| 353 | Cerebrovascular disease (PheCode 433) | GCST90475985 | 13.07 |
| 354 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502410 | 13.05 |
| 355 | DTI autoptx L3 slf l tract | GCST90385214 | 12.98 |
| 356 | AmygNuclei lh volume Accessory-Basal-nucleus | GCST90002650 | 12.90 |
| 357 | Impedance of arm right (UKB data field 23109) | GCST90468172 | 12.90 |
| 358 | Familial combined hyperlipidemia defined by Dutch criteria | GCST90104005 | 12.87 |
| 359 | HippSubfield rh volume CA1-head | GCST90002696 | 12.86 |
| 360 | Plasma 1-arachidonoyl-GPE (20:4n6)* levels in chronic kidney disease | GCST90264207 | 12.85 |
| 361 | Otosclerosis | FING00001131 | 12.84 |
| 362 | Autorefraction - 3mm cylindrical power angle (left) | Eyesight | UKBB00000064 | 12.82 |
| 363 | Volume of right central nucleus | GCST90474916 | 12.78 |
| 364 | DCTN1/ERBIN ratio | GCST90314429 | 12.77 |
| 365 | Phospholipids to total lipids in very small VLDL percentage (UKB data field 23604) | GCST90269701 | 12.75 |
| 366 | Varicose veins of lower extremities | Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified | UKBB00000894 | 12.74 |
| 367 | aparc-a2009s lh area G-cuneus | GCST90003307 | 12.72 |
| 368 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 79) | GCST90320898 | 12.72 |
| 369 | Descending aorta diameter | GCST90267391 | 12.71 |
| 370 | NIT2 levels | GCST90470051 | 12.69 |
| 371 | Pulse pressure | GCST90472783 | 12.65 |
| 372 | Heel bone mineral density (BMD) (right) | Bone-densitometry of heel | UKBB00000314 | 12.60 |
| 373 | SNX9/STIP1 ratio | GCST90315864 | 12.59 |
| 374 | aparc-Desikan rh area cuneus | GCST90003111 | 12.59 |
| 375 | IDP dMRI ProbtrackX L2 fmi | GCST90004284 | 12.57 |
| 376 | Androstenediol (3alpha, 17alpha) monosulfate (3) levels | GCST90199856 | 12.56 |
| 377 | IDP T1 FIRST left hippocampus volume | GCST90002444 | 12.47 |
| 378 | Autorefraction - 6mm strong meridian (left) | Eyesight | UKBB00000075 | 12.47 |
| 379 | BA-exvivo lh thickness V2 | GCST90003523 | 12.47 |
| 380 | FLT1/TGFB1 ratio | GCST90314857 | 12.47 |
| 381 | Primary/intrinsic cardiomyopathies (PheCode 425.1) | GCST90475951 | 12.41 |
| 382 | Whole body water mass (UKB data field 23102) | GCST90468184 | 12.39 |
| 383 | Triglycerides in VLDL (UKB data field 23408) | GCST90269505 | 12.38 |
| 384 | Medication use (antithrombotic agents) | GCST90018762 | 12.35 |
| 385 | Other mental disorders due to brain damage and dysfunction and to physical disease | FING00001072 | 12.34 |
| 386 | Heel quantitative ultrasound index (QUI), direct entry (right) | Bone-densitometry of heel | UKBB00000323 | 12.32 |
| 387 | Heel bone mineral density (BMD) T-score, automated (right) | Bone-densitometry of heel | UKBB00000317 | 12.32 |
| 388 | aseg global volume-ratio BrainSegVol-to-eTIV | GCST90002612 | 12.30 |
| 389 | GAPDH levels | GCST90469302 | 12.28 |
| 390 | Diacylglycerol_36:4_[M+H-H2O]1+ levels | GCST90060188 | 12.23 |
| 391 | Illnesses of father - None of the above (group 1) | Family history | UKBB00000345 | 12.19 |
| 392 | TPK1 levels | GCST90470943 | 12.19 |
| 393 | UFC1 levels | GCST90243245 | 12.18 |
| 394 | 3-Hydroxybutyrate levels | GCST90092811 | 12.18 |
| 395 | Tibiofemoral angle | GCST90270263 | 12.17 |
| 396 | AKT1S1/TDRKH ratio | GCST90313233 | 12.16 |
| 397 | Operative procedures - Angiocardiography of left side of heart NEC | Summary Operations | UKBB00000572 | 12.15 |
| 398 | Concentration of very large VLDL particles (UKB data field 23488) | GCST90269585 | 12.13 |
| 399 | Wears glasses or contact lenses | Eyesight | UKBB00000907 | 12.10 |
| 400 | HSPG2/IGFBP6 ratio | GCST90315091 | 12.07 |
| 401 | aparc-Desikan rh volume insula | GCST90002834 | 12.07 |
| 402 | Atherosclerosis, excluding cerebral and coronary sclerosis | FING00000123 | 12.07 |
| 403 | Keratoconus | FING00000709 | 12.03 |
| 404 | aparc-a2009s lh thickness S-postcentral | GCST90003669 | 12.03 |
| 405 | wg rh intensity-contrast caudalmiddlefrontal | GCST90003830 | 12.02 |
| 406 | Polyunsaturated fatty acid levels | GCST90502133 | 12.02 |
| 407 | Diverticulosis and diverticulitis | digestive | UKBB00000191 | 12.02 |
| 408 | Intra-ocular pressure, corneal-compensated (right) | Intraocular pressure | UKBB00000375 | 12.01 |
| 409 | aparc-a2009s lh volume S-central | GCST90002969 | 11.99 |
| 410 | Cholesteryl esters in chylomicrons and extremely large VLDL (UKB data field 23485) | GCST90269582 | 11.96 |
| 411 | X-25371 levels | GCST90200656 | 11.95 |
| 412 | BA-exvivo lh thickness BA2 | GCST90003514 | 11.92 |
| 413 | Impedance of whole body (UKB data field 23106) | GCST90468173 | 11.91 |
| 414 | Free cholesterol in medium VLDL | GCST90498965 | 11.91 |
| 415 | aparc-a2009s lh thickness G-postcentral | GCST90003630 | 11.90 |
| 416 | Hand grip strength (left) | Hand grip strength | UKBB00000300 | 11.89 |
| 417 | Illnesses of father - Heart disease | Family history | UKBB00000342 | 11.89 |
| 418 | ARHGEF12/IRAK4 ratio | GCST90313350 | 11.83 |
| 419 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T7 | ECGA000007 | 11.79 |
| 420 | Degree of unsaturation | GCST90502736 | 11.79 |
| 421 | Stable angina pectoris | GCST90018695 | 11.78 |
| 422 | IDP dMRI ProbtrackX L2 ilf l | GCST90004287 | 11.78 |
| 423 | BCAM levels | GCST90468425 | 11.76 |
| 424 | DTD1 levels | GCST90469045 | 11.72 |
| 425 | IDP dMRI ProbtrackX MO str l | GCST90004023 | 11.69 |
| 426 | Degree of unsaturation | GCST90502231 | 11.68 |
| 427 | SUGT1 levels | GCST90470780 | 11.68 |
| 428 | BA-exvivo lh volume entorhinal | GCST90002848 | 11.67 |
| 429 | rfMRI amplitudes (ICA100 node 40) | GCST90004628 | 11.67 |
| 430 | aparc-Desikan lh area cuneus | GCST90003077 | 11.67 |
| 431 | Diverticulosis | digestive | UKBB00000190 | 11.66 |
| 432 | Eye conditions (confirmatory factor analysis Factor 25) | GCST90309359 | 11.66 |
| 433 | Operative procedures - Anastomosis of mammary artery to left anterior descending coronary artery | Summary Operations | UKBB00000571 | 11.59 |
| 434 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90499288 | 11.57 |
| 435 | DCBLD2 levels | GCST90468952 | 11.56 |
| 436 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502554 | 11.56 |
| 437 | IDP dMRI TBSS L2 Anterior corona radiata R | GCST90004145 | 11.54 |
| 438 | IDP T1 FIRST right putamen volume | GCST90002441 | 11.53 |
| 439 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502173 | 11.52 |
| 440 | Social trust (aggregated) | GCST90319315 | 11.52 |
| 441 | SLC27A4/TDRKH ratio | GCST90315851 | 11.51 |
| 442 | CFB levels | GCST90468723 | 11.50 |
| 443 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T105 | ECGU000105 | 11.48 |
| 444 | CMC1 levels | GCST90468794 | 11.47 |
| 445 | DDHD2 levels | GCST90468968 | 11.47 |
| 446 | Forced expiratory volume (baseline) | GCST90565844 | 11.46 |
| 447 | GADD45GIP1 levels | GCST90469293 | 11.45 |
| 448 | RAB2B levels | GCST90470406 | 11.44 |
| 449 | DTI autoptx MD slf r tract | GCST90385242 | 11.43 |
| 450 | aparc-a2009s lh volume S-calcarine | GCST90002968 | 11.42 |
| 451 | AmygNuclei lh volume Central-nucleus | GCST90002652 | 11.38 |
| 452 | Types of physical activity in last 4 weeks - Light DIY (eg: pruning, watering the lawn) | Physical activity | UKBB00000871 | 11.36 |
| 453 | Pulse pressure | GCST90472784 | 11.34 |
| 454 | IDP dMRI ProbtrackX L3 fmi | GCST90004311 | 11.33 |
| 455 | BAX levels | GCST90468424 | 11.32 |
| 456 | Operative procedures - Carpal tunnel release | Summary Operations | UKBB00000574 | 11.31 |
| 457 | aparc-a2009s rh area G-cuneus | GCST90003381 | 11.31 |
| 458 | wg lh intensity-contrast caudalmiddlefrontal | GCST90003795 | 11.29 |
| 459 | Cholesteryl Esters in Medium VLDL | GCST90498939 | 11.28 |
| 460 | Impedance of whole body | Impedance measures | UKBB00000360 | 11.26 |
| 461 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458) | GCST90269555 | 11.26 |
| 462 | Neuroticism | GCST005232 | 11.25 |
| 463 | Carotid intima-media thickness (MTAG) | GCST90449061 | 11.25 |
| 464 | CYTL1 levels | GCST90468940 | 11.23 |
| 465 | GGCT levels | GCST90469334 | 11.21 |
| 466 | IL17RB levels | GCST90469563 | 11.21 |
| 467 | METAP2 levels | GCST90469894 | 11.19 |
| 468 | RBP5 levels | GCST90470439 | 11.18 |
| 469 | Phosphatidylcholine-O_31:0_[M+H]1+/Phosphatidylethanolamine-O_34:0_[M+H]1+ levels | GCST90060243 | 11.18 |
| 470 | CD99/MMP3 ratio | GCST90313928 | 11.16 |
| 471 | Autorefraction - 6mm strong meridian angle (right) | Eyesight | UKBB00000078 | 11.15 |
| 472 | Omega-3 fatty acid levels | GCST90502440 | 11.13 |
| 473 | Varicose veins of lower extremity | circulatory system | UKBB00000895 | 11.13 |
| 474 | CD69/NFATC1 ratio | GCST90313879 | 11.13 |
| 475 | IDP dMRI TBSS FA Anterior corona radiata L | GCST90003900 | 11.12 |
| 476 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 36) | GCST90320855 | 11.12 |
| 477 | Myocardial infarction, strict | FING00000852 | 11.11 |
| 478 | Octadecenedioylcarnitine (C18:1-DC) levels | GCST90199970 | 11.11 |
| 479 | Tonsillectomy and adenotomy | FING00001367 | 11.06 |
| 480 | Diverticular disease of intestine | Other diseases of intestines | UKBB00000189 | 11.06 |
| 481 | AOC3/ITGB1 ratio | GCST90313295 | 11.06 |
| 482 | Linoleic acid levels | GCST90498309 | 11.02 |
| 483 | Spinal stenosis (PheCode 720) | GCST90476233 | 11.01 |
| 484 | Primary coxarthrosis, bilateral | FING00001212 | 11.01 |
| 485 | Impedance of leg (left) | Impedance measures | UKBB00000358 | 11.00 |
| 486 | Cholesterol in chylomicrons and extremely large VLDL (UKB data field 23484) | GCST90269581 | 10.98 |
| 487 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 16) | GCST90320579 | 10.98 |
| 488 | Volume of left medial nucleus | GCST90474892 | 10.98 |
| 489 | Triglycerides in very small VLDL | GCST90500885 | 10.96 |
| 490 | Unstable angina pectoris | FING00001405 | 10.95 |
| 491 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 91) | GCST90320654 | 10.94 |
| 492 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 2) | GCST90320565 | 10.94 |
| 493 | COL4A1 levels | GCST90468818 | 10.92 |
| 494 | Lung function (FVC) | GCST90025998 | 10.90 |
| 495 | Gut microbiota abundance (k_Bacteria.p_Bacteroidetes.c_Bacteroidia.o_Bacteroidales.f_Rikenellaceae.g_Alistipes) | GCST90027701 | 10.90 |
| 496 | Omega-6 fatty acids levels | GCST90499177 | 10.89 |
| 497 | MTDH levels | GCST90469954 | 10.89 |
| 498 | T1 FreeSurfer a2009s lh S postcentral volume | GCST90384882 | 10.89 |
| 499 | Hand grip strength (right) | Hand grip strength | UKBB00000301 | 10.89 |
| 500 | Cholesterol in Medium VLDL | GCST90498903 | 10.87 |
| 501 | Mean diameter of VLDL particles | GCST90132734 | 10.86 |
| 502 | TANK levels | GCST90470803 | 10.86 |
| 503 | Autorefraction - 3mm strong meridian (left) | Eyesight | UKBB00000065 | 10.82 |
| 504 | Autorefraction - 3mm cylindrical power (right) | Eyesight | UKBB00000063 | 10.82 |
| 505 | Triacylglycerol_46:4_[M+NH4]1+ levels | GCST90060362 | 10.81 |
| 506 | Biological Sibling: Alzheimer's / Other Dementia | GCST90476375 | 10.80 |
| 507 | Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487) | GCST90269584 | 10.80 |
| 508 | Corneal hysteresis (left) | Intraocular pressure | UKBB00000148 | 10.77 |
| 509 | IDP dMRI TBSS MD Sagittal stratum L | GCST90004058 | 10.75 |
| 510 | Corneal resistance factor | GCST90308682 | 10.75 |
| 511 | ANKMY2 levels | GCST90468309 | 10.75 |
| 512 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T28 | ECGA000028 | 10.74 |
| 513 | NFU1 levels | GCST90470040 | 10.73 |
| 514 | Haemorrhoidal disease | GCST90014033 | 10.71 |
| 515 | Disorders of muscle, ligament, and fascia | musculoskeletal | UKBB00000187 | 10.70 |
| 516 | Pelvic width | GCST90448911 | 10.70 |
| 517 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 50) | GCST90320613 | 10.69 |
| 518 | aparc-a2009s lh area G-cingul-Post-ventral | GCST90003306 | 10.66 |
| 519 | Concentration of large VLDL particles (UKB data field 23495) | GCST90269592 | 10.65 |
| 520 | Volume of left accessory basal nucleus | GCST90474874 | 10.64 |
| 521 | Colorectal cancer (PheCode 153) | GCST008372 | 10.63 |
| 522 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T104 | ECGU000104 | 10.62 |
| 523 | VWA1 levels | GCST90471061 | 10.62 |
| 524 | Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454) | GCST90269551 | 10.61 |
| 525 | Gut microbiota abundance (k_Bacteria.p_Bacteroidetes.c_Bacteroidia.o_Bacteroidales.f_Rikenellaceae) | GCST90027668 | 10.61 |
| 526 | Total lipids in large VLDL (UKB data field 23496) | GCST90269593 | 10.60 |
| 527 | DTI TBSS MD Superior fronto-occipital fasciculus L | GCST90384615 | 10.59 |
| 528 | Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia | GCST90624744 | 10.59 |
| 529 | Luteinizing hormone levels | GCST90483478 | 10.58 |
| 530 | Waist circumference adjusted for body mass index | GCST90302892 | 10.57 |
| 531 | Heel bone mineral density (BMD) T-score, automated (left) | Bone-densitometry of heel | UKBB00000316 | 10.57 |
| 532 | COL6A3/CST3 ratio | GCST90314174 | 10.57 |
| 533 | Heel quantitative ultrasound index (QUI), direct entry (left) | Bone-densitometry of heel | UKBB00000322 | 10.57 |
| 534 | COL6A3/SMOC2 ratio | GCST90314178 | 10.56 |
| 535 | GPI levels | GCST90469391 | 10.56 |
| 536 | IDP dMRI ProbtrackX FA fmi | GCST90003936 | 10.55 |
| 537 | SYTL4 levels | GCST90470795 | 10.55 |
| 538 | Hip index | GCST012229 | 10.53 |
| 539 | Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels | GCST90200103 | 10.53 |
| 540 | CLEC1B/VSIR ratio | GCST90314106 | 10.53 |
| 541 | Atherosclerosis (PheCode 440) | GCST90475989 | 10.51 |
| 542 | ADAMTSL4 levels | GCST90468229 | 10.50 |
| 543 | HDL x low social support interaction (2df test) | GCST90570669 | 10.50 |
| 544 | Docosahexaenoic acid to total fatty acids percentage | GCST90502281 | 10.49 |
| 545 | Omega-3 fatty acid levels | GCST90502064 | 10.48 |
| 546 | IDP dMRI ProbtrackX MD unc r | GCST90004245 | 10.47 |
| 547 | CCN3/FAP ratio | GCST90313721 | 10.47 |
| 548 | ICD10 N97.0: Female infertility associated with anovulation | GCST90454223 | 10.47 |
| 549 | Cholesterol levels in very large VLDL | GCST90500518 | 10.45 |
| 550 | RET levels | GCST90470458 | 10.45 |
| 551 | APPL2 levels | GCST90468343 | 10.44 |
| 552 | Tibia length to body height ratio | GCST90270258 | 10.44 |
| 553 | CPXM2 levels | GCST90468850 | 10.43 |
| 554 | Cholesterol in Medium HDL | GCST90498495 | 10.38 |
| 555 | MDH1 levels | GCST90469876 | 10.38 |
| 556 | DTI TBSS MD Superior fronto-occipital fasciculus R | GCST90384614 | 10.36 |
| 557 | IDP dMRI TBSS L1 Superior longitudinal fasciculus L | GCST90004116 | 10.35 |
| 558 | Heel bone mineral density (BMD) (left) | Bone-densitometry of heel | UKBB00000313 | 10.32 |
| 559 | Trunk fat-free mass | Impedance measures | UKBB00000865 | 10.30 |
| 560 | Free cholesterol in small VLDL | GCST90499808 | 10.29 |
| 561 | BA-exvivo lh thickness BA4a | GCST90003517 | 10.29 |
| 562 | Comparative height size at age 10 | Early life factors | UKBB00000143 | 10.28 |
| 563 | Autorefraction - 6mm asymmetry index (left) | Eyesight | UKBB00000073 | 10.25 |
| 564 | Corneal resistance factor (left) | Intraocular pressure | UKBB00000150 | 10.25 |
| 565 | EIF4E levels | GCST90469096 | 10.23 |
| 566 | MSRA/P4HB ratio | GCST90315495 | 10.23 |
| 567 | Pulse pressure, automated reading | Cardiovascular measurement | UKBB00000715 | 10.21 |
| 568 | DCTN1/FXN ratio | GCST90314430 | 10.21 |
| 569 | Androsterone sulfate levels | GCST90200674 | 10.19 |
| 570 | Milk type used: Soy milk vs never have milk (UKB data field 1418) | GCST90132943 | 10.19 |
| 571 | Solitary pulmonary nodule (PheCode 514.2) | GCST90476044 | 10.18 |
| 572 | Spherical power (left) | Autorefraction | UKBB00000790 | 10.15 |
| 573 | Omega-6 fatty acids levels | GCST90499170 | 10.13 |
| 574 | aparc-Desikan lh thickness lateraloccipital | GCST90003455 | 10.09 |
| 575 | Pulse pressure, combined automated + manual reading | Cardiovascular measurement | UKBB00000719 | 10.09 |
| 576 | EFEMP1/FSTL3 ratio | GCST90314595 | 10.08 |
| 577 | DTI TBSS L2 Anterior limb of internal capsule R | GCST90384492 | 10.08 |
| 578 | RAB11FIP3 levels | GCST90470404 | 10.07 |
| 579 | ACAN levels | GCST90468196 | 10.07 |
| 580 | CSF1/LTBR ratio | GCST90314287 | 10.06 |
| 581 | Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482) | GCST90269579 | 10.06 |
| 582 | VPS4B levels | GCST90471047 | 10.06 |
| 583 | IDP T1 FAST ROIs R putamen | GCST90002552 | 10.05 |
| 584 | Phospholipids in very large VLDL (UKB data field 23490) | GCST90269587 | 10.04 |
| 585 | TRIAP1 levels | GCST90470963 | 10.01 |
| 586 | Phospholipids in large VLDL (UKB data field 23497) | GCST90269594 | 9.99 |
| 587 | Trunk predicted mass | Impedance measures | UKBB00000866 | 9.97 |
| 588 | MMP8/PGLYRP1 ratio | GCST90315465 | 9.96 |
| 589 | Speech-in-noise perception | GCST90044776 | 9.96 |
| 590 | CXCL11/CXCL13 ratio | GCST90314333 | 9.94 |
| 591 | LMNB2 levels | GCST90469782 | 9.94 |
| 592 | Triglycerides in small VLDL | GCST90499917 | 9.94 |
| 593 | Rotator cuff injury | GCST90044700 | 9.93 |
| 594 | ICOSLG levels | GCST90469503 | 9.92 |
| 595 | QC T1-to-standard nonlinear alignment discrepancy | GCST90006346 | 9.91 |
| 596 | 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels | GCST90200075 | 9.91 |
| 597 | Omega-3 fatty acid levels | GCST90502062 | 9.89 |
| 598 | ITPA levels | GCST90469654 | 9.87 |
| 599 | Unstable angina (intermediate coronary syndrome) | circulatory system | UKBB00000883 | 9.84 |
| 600 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502644 | 9.84 |
| 601 | Ganglion and cyst of synovium, tendon, and bursa (PheCode 727.4) | GCST90476243 | 9.83 |
| 602 | aparc-Desikan lh volume lateraloccipital | GCST90002778 | 9.82 |
| 603 | IDP dMRI ProbtrackX ICVF cgh l | GCST90004381 | 9.80 |
| 604 | LGALS3 levels | GCST90469761 | 9.79 |
| 605 | IDP dMRI TBSS ISOVF Fornix | GCST90004482 | 9.79 |
| 606 | Omega-3 fatty acids to total fatty acids percentage | GCST90502467 | 9.79 |
| 607 | DCTD levels | GCST90468957 | 9.78 |
| 608 | IDP dMRI TBSS FA Anterior corona radiata R | GCST90003899 | 9.77 |
| 609 | Operation code - haemorroidectomy / piles surgery/ banding of piles | Operations | UKBB00000557 | 9.77 |
| 610 | Hip width to body height ratio | GCST90270260 | 9.76 |
| 611 | IDP dMRI TBSS L1 Fornix | GCST90004080 | 9.76 |
| 612 | HippSubfield lh volume CA4-head | GCST90002682 | 9.74 |
| 613 | Childhood maltreatment | GCST90551844 | 9.73 |
| 614 | NUMB levels | GCST90470108 | 9.73 |
| 615 | Autorefraction - 6mm weak meridian (left) | Eyesight | UKBB00000079 | 9.72 |
| 616 | Peak expiratory flow (PEF) | Spirometry | UKBB00000638 | 9.70 |
| 617 | Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24) | GCST90309358 | 9.67 |
| 618 | Phospholipids in large VLDL | GCST90498247 | 9.63 |
| 619 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502399 | 9.59 |
| 620 | Phospholipids in chylomicrons and extremely large VLDL (UKB data field 23483) | GCST90269580 | 9.59 |
| 621 | Waist-hip index | GCST012228 | 9.59 |
| 622 | LGALS1/LGALS8 ratio | GCST90315314 | 9.58 |
| 623 | DNA methylation-estimated granulocyte proportions | GCST90014287 | 9.57 |
| 624 | Waist-to-hip ratio adjusted for BMI | GCST012230 | 9.57 |
| 625 | Holdemania abundance in stool | GCST90032432 | 9.56 |
| 626 | IDP dMRI ProbtrackX ICVF unc l | GCST90004400 | 9.56 |
| 627 | TIMM10 levels | GCST90470867 | 9.56 |
| 628 | CFH levels | GCST90468729 | 9.56 |
| 629 | Waist circumference adjusted for body mass index | GCST012226 | 9.55 |
| 630 | EPS8L2 levels | GCST90469138 | 9.53 |
| 631 | GERD | digestive | UKBB00000283 | 9.52 |
| 632 | total creatine kinase (mean, inv-norm transformed) | GCST90476413 | 9.51 |
| 633 | Heart failure and coronary heart disease | FING00000604 | 9.51 |
| 634 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502415 | 9.51 |
| 635 | RAB10 levels | GCST90470403 | 9.50 |
| 636 | NPL levels | GCST90470072 | 9.50 |
| 637 | PFDN5 levels | GCST90242340 | 9.49 |
| 638 | SCARA5 levels | GCST90470533 | 9.48 |
| 639 | Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453) | GCST90269550 | 9.47 |
| 640 | End-diastolic bi-ventricular shape (principal component 9) | GCST90448488 | 9.47 |
| 641 | Concentration of chylomicrons and extremely large VLDL particles | GCST90501010 | 9.47 |
| 642 | TNXB levels | GCST90470930 | 9.46 |
| 643 | Coronary angioplasty | FING00000357 | 9.46 |
| 644 | PSAP levels | GCST90426586 | 9.43 |
| 645 | GLB1 levels | GCST90469355 | 9.43 |
| 646 | COL6A3/TAFA5 ratio | GCST90314180 | 9.43 |
| 647 | CDK8_CCNC levels | GCST90240825 | 9.43 |
| 648 | Phospholipids to total lipids ratio in very small VLDL | GCST90093037 | 9.42 |
| 649 | Massiliomicrobiota abundance in stool | GCST90032470 | 9.42 |
| 650 | IDP dMRI ProbtrackX MO str r | GCST90004024 | 9.40 |
| 651 | MARS1 levels | GCST90469862 | 9.39 |
| 652 | aparc-DKTatlas lh volume parstriangularis | GCST90002880 | 9.38 |
| 653 | Triglycerides in large LDL | GCST90498083 | 9.37 |
| 654 | Free cholesterol in large VLDL (UKB data field 23500) | GCST90269597 | 9.37 |
| 655 | DTI TBSS L2 Retrolenticular part of internal capsule L | GCST90384497 | 9.36 |
| 656 | Triglycerides to phosphoglycerides ratio (UKB data field 23435) | GCST90269532 | 9.35 |
| 657 | high density lipoprotein cholesterol (HDLC, maximum, inv-norm transformed) | GCST90475348 | 9.35 |
| 658 | CCL8 levels | GCST90422346 | 9.33 |
| 659 | SMAD2 levels | GCST90470676 | 9.33 |
| 660 | PRDX5 levels | GCST90470318 | 9.32 |
| 661 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501092 | 9.31 |
| 662 | Free cholesterol in IDL | GCST90497561 | 9.31 |
| 663 | Eye problems/disorders - None of the above | Eyesight | UKBB00000232 | 9.31 |
| 664 | Asthma mixed form (mode) (more control exclusions) | FING00000116 | 9.31 |
| 665 | Biliary cirrhosis, NAS | FING00000213 | 9.30 |
| 666 | Pulse pressure, combined automated + manual reading | Cardiovascular measurement | UKBB00000718 | 9.30 |
| 667 | Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486) | GCST90269583 | 9.29 |
| 668 | Varicose veins | circulatory system | UKBB00000893 | 9.29 |
| 669 | DTI TBSS MD Retrolenticular part of internal capsule L | GCST90384593 | 9.27 |
| 670 | FADD/NFATC1 ratio | GCST90314771 | 9.26 |
| 671 | Smoking status - Previous | Smoking | UKBB00000781 | 9.25 |
| 672 | Congenital malformations of genital organs | FING00000333 | 9.25 |
| 673 | ATG16L1 levels | GCST90468383 | 9.25 |
| 674 | Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481) | GCST90269578 | 9.24 |
| 675 | Urine glucuronide of C10H18O2 (12)* levels in chronic kidney disease | GCST90265189 | 9.23 |
| 676 | aparc-a2009s rh area G+S-occipital-inf | GCST90003372 | 9.23 |
| 677 | IDP dMRI TBSS L2 Sagittal stratum L | GCST90004154 | 9.20 |
| 678 | Forced expiratory volume in 1-second (FEV1) | Spirometry | UKBB00000251 | 9.20 |
| 679 | Omega-3 fatty acid levels | GCST90502437 | 9.19 |
| 680 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499111 | 9.19 |
| 681 | HippSubfield lh volume presubiculum-head | GCST90002673 | 9.18 |
| 682 | CALCA levels | GCST90468528 | 9.18 |
| 683 | Cholesteryl esters in very large VLDL | GCST90500552 | 9.18 |
| 684 | PCOLCE levels | GCST90470175 | 9.17 |
| 685 | PTH1R levels | GCST90470371 | 9.17 |
| 686 | Plasma 3-hydroxyhexanoate levels in chronic kidney disease | GCST90264498 | 9.16 |
| 687 | high density lipoprotein cholesterol (HDLC, minimm, inv-norm transformed) | GCST90475356 | 9.15 |
| 688 | Triglycerides in small LDL | GCST90499712 | 9.14 |
| 689 | aparc-DKTatlas lh thickness lateraloccipital | GCST90003549 | 9.13 |
| 690 | aparc-a2009s lh volume G-front-inf-Triangul | GCST90002938 | 9.13 |
| 691 | CPQ levels | GCST90468846 | 9.13 |
| 692 | Whole body fat free mass (UKB data field 23101) | GCST90428120 | 9.12 |
| 693 | Right-hemisphere salience/ventral attention network to pallidum white-matter structural connectivity | GCST90302820 | 9.12 |
| 694 | Autorefraction - 3mm weak meridian (left) | Eyesight | UKBB00000069 | 9.12 |
| 695 | DNAJA2/FIS1 ratio | GCST90314501 | 9.10 |
| 696 | Aneurysm of iliac artery (PheCode 442.2) | GCST90475995 | 9.10 |
| 697 | Heel broadband ultrasound attenuation (left) | Bone-densitometry of heel | UKBB00000319 | 9.09 |
| 698 | DTI TBSS L3 Superior corona radiata L | GCST90384549 | 9.09 |
| 699 | Phospholipids in large VLDL | GCST90498243 | 9.08 |
| 700 | Coffee difference liking | GCST90094738 | 9.08 |
| 701 | Phospholipids in medium HDL | GCST90498635 | 9.08 |
| 702 | Fat-free mass | GCST007063 | 9.07 |
| 703 | Pelvic inlet width | GCST90448910 | 9.03 |
| 704 | Glaucoma | GCST90468129 | 9.03 |
| 705 | Triglycerides in very large VLDL | GCST90500671 | 9.03 |
| 706 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T86 | ECGU000086 | 9.01 |
| 707 | CCL5/RARRES2 ratio | GCST90313704 | 9.01 |
| 708 | Volume of left cortical nucleus | GCST90474886 | 9.01 |
| 709 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90501002 | 9.01 |
| 710 | Alzheimer's disease (MTAG) | GCST90449055 | 9.00 |
| 711 | Total triglycerides levels (UKB data field 23407) | GCST90269504 | 9.00 |
| 712 | Triacylglycerol_46:5_[M+NH4]1+ levels | GCST90060356 | 9.00 |
| 713 | BST2/CEACAM1 ratio | GCST90313537 | 9.00 |
| 714 | Left ventricular end diastole inferoseptal wall thickness | GCST90278514 | 9.00 |
| 715 | LTA4H levels | GCST90469812 | 8.99 |
| 716 | Sjögren's syndrome | GCST90018700 | 8.96 |
| 717 | Osteoporosis, osteopenia and pathological fracture | musculoskeletal | UKBB00000600 | 8.95 |
| 718 | Main speciality of consultant (recoded) - Ophthalmology | Summary Administration | UKBB00000419 | 8.95 |
| 719 | Free cholesterol in small LDL | GCST90499617 | 8.94 |
| 720 | wg lh intensity-contrast precentral | GCST90003815 | 8.93 |
| 721 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502648 | 8.93 |
| 722 | Phospholipids in very small VLDL | GCST90500851 | 8.93 |
| 723 | Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500958 | 8.92 |
| 724 | Omega-3 fatty acid levels | GCST90502441 | 8.92 |
| 725 | Pulse pressure, automated reading | Cardiovascular measurement | UKBB00000714 | 8.89 |
| 726 | high density lipoprotein cholesterol (HDLC, mean, inv-norm transformed) | GCST90475352 | 8.88 |
| 727 | Primary Raynaud’s phenomenon | GCST90271714 | 8.88 |
| 728 | VAMP8 levels | GCST90471025 | 8.87 |
| 729 | Other abnormal uterine and vaginal bleeding | FING00000919 | 8.86 |
| 730 | Hyperglyceridemia (PheCode 272.12) | GCST90475724 | 8.86 |
| 731 | PMVK levels | GCST90470272 | 8.86 |
| 732 | Phospholipids in small LDL | GCST90499673 | 8.85 |
| 733 | 5alpha-androstan-3beta,17beta-diol disulfate levels | GCST90199835 | 8.84 |
| 734 | FKBPL levels | GCST90469246 | 8.84 |
| 735 | BA-exvivo rh area V1 | GCST90003230 | 8.83 |
| 736 | NMI levels | GCST90470056 | 8.83 |
| 737 | Acetabular diameter | GCST90448906 | 8.82 |
| 738 | REST UKBBICA NET100 1111 | GCST90386965 | 8.81 |
| 739 | IDP dMRI ProbtrackX MD ilf l | GCST90004233 | 8.81 |
| 740 | NRGN levels | GCST90470083 | 8.80 |
| 741 | FHIT/PRTFDC1 ratio | GCST90314823 | 8.78 |
| 742 | C21orf58 levels | GCST90618380 | 8.77 |
| 743 | Free cholesterol in very large VLDL | GCST90500575 | 8.77 |
| 744 | TXN levels | GCST90470995 | 8.75 |
| 745 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 6) | GCST90320569 | 8.75 |
| 746 | HDL x depression interaction (2df test) | GCST90570667 | 8.74 |
| 747 | CNPY4 levels | GCST90468800 | 8.73 |
| 748 | Benign neoplasm: Colon, unspecified | FING00000172 | 8.73 |
| 749 | Free cholesterol in very large VLDL (UKB data field 23493) | GCST90269590 | 8.73 |
| 750 | MATN2/SCARA5 ratio | GCST90315388 | 8.72 |
| 751 | IL1R2 levels | GCST90469572 | 8.72 |
| 752 | Omega-3 fatty acids to total fatty acids percentage | GCST90502466 | 8.71 |
| 753 | ALB levels | GCST90269576 | 8.68 |
| 754 | aparc-DKTatlas lh volume lateraloccipital | GCST90002871 | 8.67 |
| 755 | IDP dMRI TBSS ICVF Uncinate fasciculus R | GCST90004371 | 8.67 |
| 756 | Other hammer toe(s) (acquired) | FING00001054 | 8.67 |
| 757 | Thoracic or lumbosacral neuritis or radiculitis, unspecified (PheCode 763) | GCST90476268 | 8.65 |
| 758 | Angina pectoris (PheCode 411.3) | GCST90475933 | 8.65 |
| 759 | Free cholesterol in medium LDL | GCST90498767 | 8.63 |
| 760 | DUT levels | GCST90469054 | 8.63 |
| 761 | THTPA levels | GCST90470860 | 8.62 |
| 762 | aparc-a2009s lh area G-oc-temp-med-Lingual | GCST90003318 | 8.61 |
| 763 | IDP dMRI ProbtrackX FA atr l | GCST90003927 | 8.59 |
| 764 | Prescriptions - prostaglandin analog | UKBB00000697 | 8.59 |
| 765 | Inguinal hernia (PheCode 550.1) | GCST90476060 | 8.59 |
| 766 | Docosahexaenoic acid levels | GCST90502258 | 8.59 |
| 767 | GMFG levels | GCST90469366 | 8.58 |
| 768 | CLSTN2/MATN2 ratio | GCST90314143 | 8.58 |
| 769 | Volume of left anterior amygdaloid area | GCST90474871 | 8.58 |
| 770 | Contracture of palmar fascia [Dupuytren's disease] | musculoskeletal | UKBB00000146 | 8.58 |
| 771 | aparc-DKTatlas lh area lateraloccipital | GCST90003243 | 8.58 |
| 772 | aparc-DKTatlas lh thickness cuneus | GCST90003543 | 8.56 |
| 773 | aparc-pial rh area inferiorparietal | GCST90003181 | 8.56 |
| 774 | Main speciality of consultant (recoded) - Cardiology | Summary Administration | UKBB00000414 | 8.56 |
| 775 | CCL13/CCL2 ratio | GCST90313675 | 8.55 |
| 776 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502179 | 8.55 |
| 777 | TOP2B levels | GCST90470934 | 8.53 |
| 778 | Triglycerides in medium VLDL | GCST90499065 | 8.52 |
| 779 | T1 FreeSurfer BA lh BA2 exvivo volume | GCST90385534 | 8.52 |
| 780 | RAPGEF2 levels | GCST90470426 | 8.51 |
| 781 | MRAP levels | GCST90089910 | 8.50 |
| 782 | IL3RA levels | GCST90469596 | 8.50 |
| 783 | PAMR1 levels | GCST90470155 | 8.49 |
| 784 | IDP dMRI TBSS MD External capsule L | GCST90004060 | 8.49 |
| 785 | Triglycerides in HDL | GCST90497464 | 8.49 |
| 786 | IDP dMRI ProbtrackX ICVF ar r | GCST90004376 | 8.48 |
| 787 | GRHPR levels | GCST90469400 | 8.47 |
| 788 | Triglycerides to total lipids in very large HDL percentage (UKB data field 23633) | GCST90269730 | 8.47 |
| 789 | BA-exvivo lh thickness BA3b | GCST90003516 | 8.47 |
| 790 | Levulinate 4-oxovalerate levels | GCST90243545 | 8.46 |
| 791 | Operation code - squint correction | Operations | UKBB00000566 | 8.46 |
| 792 | ERBIN/TBC1D23 ratio | GCST90314698 | 8.44 |
| 793 | CFHR5 levels | GCST90468728 | 8.43 |
| 794 | DTI TBSS MD Superior longitudinal fasciculus R | GCST90384612 | 8.42 |
| 795 | FOXO1/NFATC1 ratio | GCST90314873 | 8.42 |
| 796 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T11 | ECGA000011 | 8.42 |
| 797 | Dissection of aorta | FING00000467 | 8.41 |
| 798 | Fractured/broken bones in last 5 years | Medical conditions | UKBB00000258 | 8.41 |
| 799 | ALB levels | GCST90497108 | 8.40 |
| 800 | rfMRI connectivity (ICA100 edge 961) | GCST90005814 | 8.40 |
| 801 | Cholesterol in Small VLDL | GCST90499746 | 8.39 |
| 802 | Other intervertebral disc disorders | FING00001063 | 8.39 |
| 803 | X-26109 levels | GCST90200671 | 8.38 |
| 804 | Free cholesterol in very small VLDL | GCST90500774 | 8.38 |
| 805 | IDP dMRI TBSS MD Cingulum cingulate gyrus R | GCST90004061 | 8.38 |
| 806 | XIAP levels | GCST90471083 | 8.36 |
| 807 | HSPB1 levels | GCST90469489 | 8.34 |
| 808 | Phenylacetylcarnitine levels | GCST90199993 | 8.33 |
| 809 | SEC31A levels | GCST90470563 | 8.33 |
| 810 | Autorefraction - 6mm asymmetry angle (left) | Eyesight | UKBB00000072 | 8.31 |
| 811 | Cholesterol esters in very small VLDL | GCST90500740 | 8.30 |
| 812 | Physical activity (Total log acceleration 8am-10am) | GCST90061413 | 8.29 |
| 813 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 71) | GCST90320634 | 8.28 |
| 814 | Triglycerides to Total Lipids in Small LDL percentage | GCST90499740 | 8.28 |
| 815 | Autorefraction - 3mm strong meridian (right) | Eyesight | UKBB00000066 | 8.28 |
| 816 | LDLR levels | GCST90179346 | 8.28 |
| 817 | Triglycerides in medium LDL | GCST90498870 | 8.27 |
| 818 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500920 | 8.27 |
| 819 | Cerebrospinal fluid unidentified metabolite levels (HILIC Metabolomics ID: 3.04_132.06) | GCST90291582 | 8.25 |
| 820 | Pulse pressure, automated reading, adjusted by medication | Cardiovascular measurement | UKBB00000717 | 8.25 |
| 821 | Trigger finger | FING00001376 | 8.24 |
| 822 | Phospholipids in large LDL | GCST90498053 | 8.23 |
| 823 | Unstable angina pectoris | GCST90018712 | 8.23 |
| 824 | Monounsaturated fatty acid levels | GCST90499090 | 8.23 |
| 825 | Urine taurodeoxycholic acid 3-sulfate levels in chronic kidney disease | GCST90266045 | 8.23 |
| 826 | aparc-DKTatlas rh area pericalcarine | GCST90003284 | 8.22 |
| 827 | IDP dMRI ProbtrackX MD fmi | GCST90004230 | 8.22 |
| 828 | Triglyceride to HDL cholesterol ratio | GCST90295951 | 8.22 |
| 829 | IDP dMRI TBSS L2 Superior corona radiata R | GCST90004147 | 8.22 |
| 830 | Autorefraction - 6mm strong meridian (right) | Eyesight | UKBB00000076 | 8.22 |
| 831 | DTI TBSS L1 Splenium of corpus callosum | GCST90384432 | 8.20 |
| 832 | Impedance of leg (right) | Impedance measures | UKBB00000359 | 8.17 |
| 833 | Cholesterol levels in very small VLDL | GCST90500700 | 8.17 |
| 834 | Triglycerides in medium VLDL (UKB data field 23508) | GCST90269605 | 8.16 |
| 835 | CTSH levels | GCST90468913 | 8.16 |
| 836 | Glycated hemoglobin levels | GCST90566424 | 8.16 |
| 837 | CLMP/TNFRSF19 ratio | GCST90314136 | 8.15 |
| 838 | Pulse pressure, combined automated + manual reading, adjusted by medication | Cardiovascular measurement | UKBB00000721 | 8.14 |
| 839 | Lymphoid leukemia, chronic (PheCode 204.12) | GCST90475613 | 8.13 |
| 840 | IDP dMRI ProbtrackX L2 unc r | GCST90004299 | 8.13 |
| 841 | Hip index | GCST90020026 | 8.13 |
| 842 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502077 | 8.13 |
| 843 | Volume of right accessory basal nucleus | GCST90474907 | 8.12 |
| 844 | FGFR2 levels | GCST90469233 | 8.11 |
| 845 | COL6A3/COLEC12 ratio | GCST90314173 | 8.10 |
| 846 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 44) | GCST90320863 | 8.09 |
| 847 | Corneal dystrophy (PheCode 364.5) | GCST90475864 | 8.09 |
| 848 | Omega-3 fatty acids to total fatty acids percentage | GCST90502090 | 8.09 |
| 849 | GPIHBP1 levels | GCST90469390 | 8.08 |
| 850 | SSC5D levels | GCST90470748 | 8.08 |
| 851 | Volume of left medial nucleus | GCST90474976 | 8.07 |
| 852 | PRTFDC1 levels | GCST90470346 | 8.06 |
| 853 | Free cholesterol in large LDL | GCST90497981 | 8.06 |
| 854 | Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501045 | 8.05 |
| 855 | Kidney transplant status | FING00000710 | 8.04 |
| 856 | DKKL1 levels | GCST90469000 | 8.04 |
| 857 | BOC levels | GCST90468458 | 8.04 |
| 858 | total creatine kinase (minimum, inv-norm transformed) | GCST90476416 | 8.01 |
| 859 | Degree of unsaturation | GCST90500175 | 8.00 |
| 860 | Autorefraction - 6mm weak meridian (right) | Eyesight | UKBB00000080 | 7.97 |
| 861 | Free cholesterol in very large VLDL | GCST90500581 | 7.97 |
| 862 | NRP1 levels | GCST90470085 | 7.97 |
| 863 | DTI TBSS L2 Superior fronto-occipital fasciculus L | GCST90384519 | 7.97 |
| 864 | DTI autoptx MD str l tract | GCST90385243 | 7.97 |
| 865 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500508 | 7.96 |
| 866 | STAT2 levels | GCST90470758 | 7.95 |
| 867 | IDP T1 FAST ROIs L hippocampus | GCST90002555 | 7.94 |
| 868 | SNAP29/TJAP1 ratio | GCST90315861 | 7.94 |
| 869 | NDUFB7 levels | GCST90470015 | 7.93 |
| 870 | CNTN1 levels | GCST90468803 | 7.92 |
| 871 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502414 | 7.92 |
| 872 | TTR levels | GCST90470985 | 7.92 |
| 873 | DFFA levels | GCST90468987 | 7.90 |
| 874 | NPY levels | GCST90470081 | 7.90 |
| 875 | FAM20A levels | GCST90469185 | 7.89 |
| 876 | Takes medication for Glaucoma? | GCST90475384 | 7.87 |
| 877 | C8B levels | GCST90468503 | 7.86 |
| 878 | IDP dMRI ProbtrackX L2 atr l | GCST90004275 | 7.86 |
| 879 | aparc-DKTatlas rh volume lateraloccipital | GCST90002902 | 7.85 |
| 880 | Degree of unsaturation | GCST90502225 | 7.84 |
| 881 | MAP4K5 levels | GCST90469855 | 7.79 |
| 882 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T16 | ECGA000016 | 7.78 |
| 883 | aparc-Desikan lh volume parstriangularis | GCST90002787 | 7.77 |
| 884 | PMVK/PRTFDC1 ratio | GCST90315695 | 7.77 |
| 885 | Acquired absence of organs, not elsewhere classified | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000005 | 7.76 |
| 886 | DGKA levels | GCST90468989 | 7.76 |
| 887 | Corneal edema (PheCode 364.2) | GCST90475862 | 7.75 |
| 888 | IDP dMRI TBSS L2 Uncinate fasciculus R | GCST90004167 | 7.75 |
| 889 | CHMP6 levels | GCST90468747 | 7.74 |
| 890 | Autorefraction - 3mm weak meridian (right) | Eyesight | UKBB00000070 | 7.74 |
| 891 | Heel bone mineral density | GCST006288 | 7.74 |
| 892 | TNFSF10 levels | GCST90012011 | 7.73 |
| 893 | ITGB1 levels | GCST90469643 | 7.73 |
| 894 | aparc-Desikan rh area pericalcarine | GCST90003127 | 7.72 |
| 895 | STROKE | FING00001336 | 7.72 |
| 896 | ROBO1/SPON1 ratio | GCST90315783 | 7.71 |
| 897 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502069 | 7.71 |
| 898 | SMAD1 levels | GCST90470675 | 7.71 |
| 899 | Other peripheral nerve disorders | neurological | UKBB00000618 | 7.70 |
| 900 | Subclinical hyperthyroidism in pregnancy | GCST90435199 | 7.70 |
| 901 | Pulse pressure | GCST90310296 | 7.68 |
| 902 | Treatment speciality of consultant (recoded) - Ophthalmology | Summary Administration | UKBB00000835 | 7.67 |
| 903 | Peripheral vascular disease | GCST90086134 | 7.67 |
| 904 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60) | GCST90320623 | 7.65 |
| 905 | Right-hemisphere dorsal attention network to pallidum white-matter structural connectivity | GCST90302809 | 7.65 |
| 906 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499109 | 7.63 |
| 907 | Triglyceride levels in large VLDL | GCST90092878 | 7.62 |
| 908 | Dupuytren's disease | GCST90301252 | 7.62 |
| 909 | RBP7 levels | GCST90470440 | 7.62 |
| 910 | Average diameter for LDL particles | GCST90498457 | 7.62 |
| 911 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T68 | ECGU000068 | 7.61 |
| 912 | DTI TBSS MD Superior longitudinal fasciculus L | GCST90384613 | 7.61 |
| 913 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T135 | ECGU000135 | 7.59 |
| 914 | CLIP2/NT5C3A ratio | GCST90314129 | 7.59 |
| 915 | Takes medication for coronary artery/ coronary heart disease? | GCST90475199 | 7.58 |
| 916 | IL31RA levels | GCST90469589 | 7.57 |
| 917 | Phospholipids to total lipids in small LDL percentage (UKB data field 23624) | GCST90269721 | 7.56 |
| 918 | Operation code - inguinal/femoral hernia repair | Operations | UKBB00000561 | 7.55 |
| 919 | ZNRF4 levels | GCST90471104 | 7.55 |
| 920 | Non-cancer illness code, self-reported - migraine | Medical conditions | UKBB00000520 | 7.54 |
| 921 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500929 | 7.53 |
| 922 | Triglyceride to phosphoglyceride ratio | GCST90454483 | 7.53 |
| 923 | Drusen (degenerative) of retina (PheCode 362.27) | GCST90475855 | 7.53 |
| 924 | A body shape index | GCST012231 | 7.53 |
| 925 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500692 | 7.53 |
| 926 | Phospholipids in medium LDL | GCST90498831 | 7.52 |
| 927 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T85 | ECGU000085 | 7.52 |
| 928 | PTPRF/PTPRS ratio | GCST90315751 | 7.52 |
| 929 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502147 | 7.51 |
| 930 | Cholesteryl esters to total lipids in small LDL percentage (UKB data field 23626) | GCST90269723 | 7.50 |
| 931 | JPT2 levels | GCST90469663 | 7.50 |
| 932 | ACOT13 levels | GCST90468200 | 7.50 |
| 933 | Ratio of polyunsaturated fatty acids to monounsaturated fatty acids | GCST90092940 | 7.49 |
| 934 | High density lipoprotein cholesterol levels | GCST90278635 | 7.49 |
| 935 | Cerebrospinal fluid 5-methylthioadenosine (MTA) levels | GCST90318216 | 7.47 |
| 936 | IDP dMRI TBSS L1 External capsule L | GCST90004108 | 7.47 |
| 937 | PPP3R1 levels | GCST90470307 | 7.46 |
| 938 | aseg global volume 4th-Ventricle | GCST90002600 | 7.46 |
| 939 | PTPN6/SNAP23 ratio | GCST90315747 | 7.46 |
| 940 | Corneal opacity and other disorders of cornea (PheCode 364) | GCST90475861 | 7.45 |
| 941 | Total lipid levels in very large VLDL | GCST90093022 | 7.44 |
| 942 | IDP T2 FLAIR BIANCA WMH volume | GCST90003862 | 7.44 |
| 943 | aparc-DKTatlas lh area cuneus | GCST90003237 | 7.44 |
| 944 | Concentration of chylomicrons and extremely large VLDL particles | GCST90501015 | 7.43 |
| 945 | CD69/SNAP29 ratio | GCST90313887 | 7.43 |
| 946 | Intracerebral hemorrhage | GCST90018650 | 7.43 |
| 947 | Cholesteryl Esters in HDL | GCST90497368 | 7.43 |
| 948 | SMPD1 levels | GCST90470684 | 7.42 |
| 949 | IGF1 levels | GCST90025989 | 7.42 |
| 950 | Phosphatidylglycerol (34:1) levels | GCST90025061 | 7.42 |
| 951 | TNFRSF10A levels | GCST90470899 | 7.40 |
| 952 | Ischemic heart disease (PheCode 411) | GCST90475929 | 7.40 |
| 953 | wg lh intensity-contrast middletemporal | GCST90003806 | 7.40 |
| 954 | Triglyceride levels in very large VLDL | GCST90093026 | 7.39 |
| 955 | CCN1 levels | GCST90468587 | 7.39 |
| 956 | Arm predicted mass (right) | Impedance measures | UKBB00000050 | 7.39 |
| 957 | Omega-3 fatty acid levels | GCST90502436 | 7.37 |
| 958 | Operative procedures - Haemorrhoidectomy | Summary Operations | UKBB00000580 | 7.37 |
| 959 | Paradoxical eczema in biologic-treated plaque psoriasis | GCST90162550 | 7.37 |
| 960 | Constipation | FING00000348 | 7.37 |
| 961 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501091 | 7.35 |
| 962 | USP25 levels | GCST90471019 | 7.34 |
| 963 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90500994 | 7.34 |
| 964 | Triglycerides in IDL | GCST90497661 | 7.33 |
| 965 | Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500983 | 7.33 |
| 966 | Treatment speciality of consultant (recoded) - Cardiology | Summary Administration | UKBB00000829 | 7.33 |
| 967 | IDP dMRI ProbtrackX ICVF unc r | GCST90004401 | 7.33 |
| 968 | IDP dMRI TBSS FA Tapetum R | GCST90003923 | 7.33 |
| 969 | aparc-Desikan lh thickness paracentral | GCST90003461 | 7.32 |
| 970 | Triglycerides in very small VLDL | GCST90500873 | 7.32 |
| 971 | TNFRSF19 levels | GCST90470909 | 7.31 |
| 972 | FAM172A levels | GCST90469184 | 7.31 |
| 973 | MED18/SMAD1 ratio | GCST90315413 | 7.31 |
| 974 | Left-hemisphere dorsal attention network to thalamus white-matter structural connectivity | GCST90302701 | 7.30 |
| 975 | Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500992 | 7.30 |
| 976 | Hip circumference adjusted for BMI | GCST012227 | 7.29 |
| 977 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502372 | 7.29 |
| 978 | COLEC12/LTBR ratio | GCST90314182 | 7.29 |
| 979 | Metabolonic lactone sulfate levels | GCST90200257 | 7.28 |
| 980 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502566 | 7.28 |
| 981 | IDP dMRI TBSS MD Pontine crossing tract | GCST90004028 | 7.28 |
| 982 | systolic blood pressure (SBP, maximum, inv-normal transformed) | GCST90476400 | 7.27 |
| 983 | aseg lh volume Putamen | GCST90002622 | 7.26 |
| 984 | Familial combined hyperlipidemia defined by Consensus criteria | GCST90104006 | 7.26 |
| 985 | Alcohol abuse, main dg (more control exclusions) | FING00000049 | 7.25 |
| 986 | Pulse pressure, combined automated + manual reading, adjusted by medication | Cardiovascular measurement | UKBB00000720 | 7.25 |
| 987 | Biological Sibling: Coronary Artery / Coronary Heart Disease | GCST90476370 | 7.25 |
| 988 | Intraocular pressure | GCST004074 | 7.25 |
| 989 | Cholesterol in Large LDL | GCST90497919 | 7.25 |
| 990 | TXNRD1 levels | GCST90470994 | 7.24 |
| 991 | AmygNuclei rh volume Medial-nucleus | GCST90002663 | 7.24 |
| 992 | CALCOCO2 levels | GCST90468531 | 7.23 |
| 993 | ALB levels | UKBB00000019 | 7.23 |
| 994 | Cholesteryl ester_18:0_[M+NH4]1+ levels | GCST90060222 | 7.22 |
| 995 | THBS2 levels | GCST90470854 | 7.22 |
| 996 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502581 | 7.21 |
| 997 | IDP dMRI TBSS L1 Posterior limb of internal capsule L | GCST90004094 | 7.21 |
| 998 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502153 | 7.21 |
| 999 | IDP dMRI ProbtrackX MD fma | GCST90004229 | 7.21 |
| 1000 | Spondylolisthesis/Spondylolysis | FING00001324 | 7.19 |